Clinical trials: Cannabidiol
Schizophrenia, Schizoaffective Disorder
Cannabidiol Treatment of Cognitive Dysfunction in Schizophrenia
This study is a six-week, randomized, placebo-controlled, fixed dose trial comparing cannabidiol Vs. placebo added to a stable dose of antipsychotic medications in patients diagnosed with schizophrenia.
- Trial name
- NCT00588731
- Testing
- Cannabidiol
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Yale University
Acne Vulgaris
Evaluation of BTX 1503 in Patients With Moderate to Severe Acne Vulgaris
The objective of this study is to assess safety and efficacy of various doses of BTX 1503 liquid formulation in subjects with moderate to severe acne vulgaris of the face.
- Trial name
- NCT03573518
- Testing
- BTX 1503, Vehicle
- Where
- 36 sites in United States, Australia
- Volunteers
- 368 people
- Sponsor
- Botanix Pharmaceuticals
Essential Tremor
Trial of Cannabis for Essential Tremor
This is a pilot trial to evaluate the safety and efficacy of a combined oral formulation of THC and CBD in patients with Essential Tremor.
- Trial name
- NCT03805750
- Testing
- CBD/THC
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of California, San Diego
Smoking, Marijuana
Laboratory Study of Cannabidiol on the Effects of Smoked Marijuana
The objective of this study is to assess the effects of oral cannabidiol (CBD; 0, 200, 400, 800 mg) on smoked marijuana's (0, 5.6% THC) subjective, reinforcing, cognitive, and cardiovascular effects.
- Trial name
- NCT01844687
- Testing
- CBD
- Where
- 3 sites in United States
- Volunteers
- 50 people
- Sponsor
- National Institute on Drug Abuse (NIDA)
Prader-Willi Syndrome
Cannabidiol Oral Solution for the Treatment of Patients With Prader-Willi Syndrome
The primary objective of this study is to assess the efficacy of cannabidiol oral solution on hyperphagia-related behavior in patients with Prader-Willi Syndrome (PWS).
- Trial name
- NCT02844933
- Testing
- Cannabidiol
- Where
- 7 sites in United States
- Volunteers
- 7 people
- Sponsor
- Radius Pharmaceuticals, Inc.
Rett Syndrome, RTT
Efficacy and Safety of Cannabidiol Oral Solution (GWP42003-P, CBD-OS) in Patients With Rett Syndrome
To evaluate the efficacy of cannabidiol oral solution (GWP42003-P, CBD-OS) in reducing symptom severity when compared with placebo, in participants with Rett syndrome.
- Trial name
- ARCH (NCT03848832)
- Testing
- GWP42003-P
- Where
- 26 sites in United States, Italy and 2 more
- Volunteers
- 29 people
- Sponsor
- Jazz Pharmaceuticals
Lennox-Gastaut Syndrome, Dravet Syndrome
The Effects of Cannabidiol (CBD) on Electrical and Autonomic Cardiac Function in Children With Severe Epilepsy
The investigators propose to study the effects of cannabidiol (CBD) on cardiac electrical function and the autonomic nervous system in children with Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS), when the CBD is…
- Trial name
- CBD1 (NCT02815540)
- Testing
- 12-Lead ECG, Cannabidiol
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Gillette Children's Specialty Healthcare
Alcohol Use Disorder
Effects of Cannabidiol in Alcohol Use Disorder
The goal of the proposed project is to begin rigorous study of the clinically relevant effects of non-psychoactive phytocannabinoid cannabidiol (CBD) in patients with severe alcohol use disorder (AUD).
- Trial name
- NCT03252756
- Testing
- Phytocannabinoid cannabidiol (CBD)
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- NYU Langone Health
Seizures Associated With EMAS
Efficacy and Safety of GWP42003-P Oral Solution in Children With Epilepsy With Myoclonic-atonic Seizures
The primary aim of Part A of the study to assess the efficacy and tolerability of GWP42003-P compared to placebo as an adjunctive treatment for children with Epilepsy with myoclonic-atonic seizures (EMAS) -associated seizures.
- Trial name
- NCT05288283
- Testing
- GWP42003-P
- Where
- 14 sites in United States, Italy
- Volunteers
- 3 people
- Sponsor
- Jazz Pharmaceuticals
Cannabidiol, Drug Induced Liver Injury
Clinical Study to Evaluate Cannabidiol Liver Enzyme Elevations and Drug Interactions
Cannabidiol (CBD) is available as a prescription drug product for the treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex.
- Conditions
- Cannabidiol, Drug Induced Liver Injury, Drug Interaction
- Trial name
- NCT06192589
- Testing
- Cannabidiol, Citalopram, Morphine
- Where
- United States
- Volunteers
- 241 people, healthy volunteers welcome
- Sponsor
- Food and Drug Administration (FDA)
Opioid Use Disorder
Cannabidiol in the Treatment of Opioid Use Disorder
The long-term goal of the project is to determine whether cannabidiol (CBD) can reduce craving and relapse in individuals with opioid use disorder (OUD).
- Trial name
- NCT06206291
- Testing
- Cannabidiol (CBD) 200mg, Cannabidiol (CBD) 400mg
- Where
- United States
- Volunteers
- 76 people
- Sponsor
- Yasmin Hurd
Opioid-use Disorder
Cannabidiol Use to Reduce Cravings in Individuals With Opioid Use Disorder on Buprenorphine
The purpose of this week-long study is to determine the impact of cannabidiol on cue-induced cravings among individuals with opioid use disorder who are stable on sublingual buprenorphine treatment.
- Trial name
- CURB (NCT04192370)
- Testing
- Cannabidiol 600mg
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Brigham and Women's Hospital
Obsessive-Compulsive Disorder, Trichotillomania (Hair-Pulling Disorder)
Epidiolex in Obsessive Compulsive Disorder and Related Disorders
The primary objective of the proposed study is to evaluate the safety and efficacy of Epidiolex (cannabidiol) in adults with obsessive compulsive and related disorders (OCRDs).
- Conditions
- Obsessive-Compulsive Disorder, Trichotillomania (Hair-Pulling Disorder), Tourette Syndrome, Hoarding Disorder
- Trial name
- NCT04978428
- Testing
- Cannabidiol
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of Chicago
Prader-Willi Syndrome
A Study to Assess the Long-Term Safety of Pharmaceutical Grade Synthetic Cannabidiol Oral Solution in Participants With Prader-Willi Syndrome
The objective of this study is to assess the long-term safety and tolerability of Cannabidiol Oral Solution (CBD) in participants with Prader-Willi Syndrome.
- Trial name
- NCT03458416
- Testing
- Cannabidiol Oral Solution
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Radius Pharmaceuticals, Inc.
Rett Syndrome, RTT
A Long-term Safety Study of Cannabidiol Oral Solution (GWP42003-P, CBD-OS) in Patients With Rett Syndrome
This study will be conducted to evaluate the long-term safety of cannabidiol oral solution (GWP42003-P, CBD-OS) in participants with Rett syndrome.
- Trial name
- NCT04252586
- Testing
- GWP42003-P
- Where
- 31 sites in United States, Australia and 4 more
- Volunteers
- 21 people
- Sponsor
- Jazz Pharmaceuticals
Prevention
RCT-Consumer Perceptions of Cannabidiol (CBD) Health Claims
Cannabidiol (CBD) cannot be marketed as having therapeutic benefits (without FDA's approval), be false or misleading to consumers, or convey the products are approved or endorsed by the FDA.
- Trial name
- RCT (NCT06800066)
- Testing
- Purchase Behavior - (Non-CBD ads), Purchase Behavior - (CBD ads)
- Where
- United States
- Volunteers
- 460 people, healthy volunteers welcome
- Sponsor
- Wake Forest University Health Sciences
Parkinson's Disease
A Study of Tolerability and Efficacy of Cannabidiol on Tremor in Parkinson's Disease
The major purpose of the Stage 1 is to study the safety and tolerability of the proposed dosage regimen of the study drug. The form of cannabidiol (CBD) used in this study is GWP42003, supplied by GW Pharmaceuticals.
- Trial name
- NCT02818777
- Testing
- cannabidiol
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- University of Colorado, Denver
Odontalgia, Toothache
CBD for Dental Pain
The purpose of this study is to evaulate CBD as a therapeutic approach for dental pain. Eligible subjects presented with emergency dental pain will be give a single dose of Epidiolex (FDA-approved CBD) or placebo and will be…
- Trial name
- NCT04642404
- Testing
- Epidiolex 100 mg/mL Oral Solution
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Epilepsy, Lennox Gastaut Syndrome
Efficacy and Safety of GWP42003-P for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults
The primary objective of this study was to evaluate the efficacy of GWP42003-P as adjunctive treatment in reducing the number of drop seizures when compared with placebo in participants with Lennox-Gastaut syndrome (LGS).
- Trial name
- GWPCARE3 (NCT02224560)
- Testing
- GWP42003-P
- Where
- 29 sites in United States, France and 2 more
- Volunteers
- 225 people
- Sponsor
- Jazz Pharmaceuticals
Advanced Breast Cancer, Anxiety
RCT of CBD for Anxiety in Advanced Breast Cancer
This research study is investigating use of a single dose of cannabidiol (CBD) to help manage anticipatory anxiety in participants with advanced breast cancer poised to undergo computed tomography (CT) or positron emission…
- Conditions
- Advanced Breast Cancer, Anxiety, CBD
- Trial name
- NCT04482244
- Testing
- Cannabidiol
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Dana-Farber Cancer Institute